



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

D. Standring, *et al.*

Serial No.: 10/662,641

Confirmation No. 2664

Filed: September 15, 2003

For: **β-L-2'-DEOXYNUCLEOSIDES FOR THE  
TREATMENT OF RESISTANT HBV  
STRAINS AND COMBINATION  
THERAPIES**

§ Group Art Unit: Unassigned

§ Examiner: Unassigned

§ Atty Docket: 06171.105097  
(IDX 1021 US)

STATEMENT AS REQUIRED UNDER 37 C.F.R. § 1.821(f), (g)

**Mail Stop Missing Parts**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING  
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

6/9/2004


Monte P. Thaddeus  
Signature

Sir:

Submitted herewith is a computer readable form and a paper copy of the sequence listing of those sequences in the captioned patent application. The computer readable form of the sequence listing is the same as the paper copy of the sequence listing, i.e. the information recorded on the form is identical to the written sequence listing. The sequence information provided in the Specification is also the same as the sequence listing of the enclosed computer readable and paper forms of the sequence listing.

Applicant further states that this submission, filed in accordance with 37 C.F.R. §1.821(g), does not include new matter.

Respectfully submitted,



Monte R. Rhodes, Ph.D.  
Reg. No. 54,396  
Customer No. 20786  
AGENT FOR ASSIGNEE,  
IDENIX PHARMACEUTICALS, INC.

King & Spalding, LLP  
191 Peachtree Street  
Atlanta, GA 30303-1763  
(404) 572-2574

Date: June 9, 2004